StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NYSE NAVB opened at $0.00 on Monday. The company has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.04. The company has a market capitalization of $20,016.80, a P/E ratio of 0.00 and a beta of 0.76. Navidea Biopharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.15.
Navidea Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Progress Software Stock Back in the Green After Beating Forecasts
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.